Konsul'tirovanie po primeneniyu levonorgestrelvydelyayushchey vnutrimatochnoy sistemy "Mirena"


Cite item

Full Text

Abstract

Левоноргестрелвыделяющая внутриматочная система "Мирена" (ЛНГ ВМС) была разработана (Лейрас АО, Турку, Финляндия) как средство для пролонгированной, обратимой контрацепции, сочетающее преимущества внутриматочного и гормонального методов предохранения от беременности. Консультирование о применении внутриматочной системы "Мирена" должно включать информацию не только о контрацептивном, но и неконтрацептивных преимуществах метода.

About the authors

M A Tarasova

НИИ акушерства и гинекологии им. Д.О.Отта РАМН, Санкт-Петербург

V A Grigor'eva

НИИ акушерства и гинекологии им. Д.О.Отта РАМН, Санкт-Петербург

References

  1. Pakarinen P, Toivonen J, Luukkainen T. Therapeutic Use of the LNG IDS, and Counseling. Seminars in reproductive medicine/volume 19, number 4 2001; 365–72.
  2. Nilsson C.G, Lahteenmaki P.L, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel - releasing intrauterine device. Fertil Steril 1984; 41: 52–SS.
  3. Barbosa I, Bakos O, Olsson S.E et al. Ovarian function during use of a levonorgestrel - releasing IUD. Contraception 1990; 42: 51–66.
  4. Andersson K, Mattsson L-O, Rybo G, Stanberg E. Intrauterine release of levonorgestrel: a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963–7.
  5. Faundes A, Alvarez F, Diaz J. A Latin American experience with levonorgestrel IUD. Ann Med 1993; 25: 149–53.
  6. Sivin I, Alvarez F, Diaz J et al. Intrauterine contraception with qt copper and with levonorgestrel: a randomised study of the Tcu380Ag and levonorgestrel 20 ug/D devices. Contraception 1984; 30: 443–56.
  7. Lei Z-W, Wu S.C, Garceau R.J et al. Effects of pretreatment counseling on discontinuation rates in Chinese women given depo - meclroxyprogesterone acetate for contraception. Contraception 1996; 53: 357–61.
  8. Luukkainen T, Lahteenmaki P, Toivonen J. Three years' experience with levonorgestrel - releasing intrauterine device and Norplant-2 implants: a randomized comparative study. Adv Contracept 1992; 8: 105–14.
  9. Nilsson C.G, Luukkainen T, Arko H. Endometrial morphology of women using a d - norgesrrel - releasing intrauterine device. Fertil Steril 1978; 29: 397–401,
  10. Silverberg S.G, Haukkamaa M, Arko H et al. Endometrial morphology during long - term use of levonorgestrel - releasing intrauterine devices. Int J Gynecol Pathol 1986; 3: 235–41.
  11. Jones R.L, Critchley H.O. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 2000; 15 (suppl. 3): 162–72.
  12. Rutanen E-M. Insulin - like growth factors and insulin - like growth factor binding proteins in the endometrium: effect of intrauterine levonorgestrel delivery. Hum Reprod 2000; 15 (suppl. 3): 173–81.
  13. Andersson J.K, Rybo G. Levonorgestrel - releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 690–4.
  14. Milsora I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid and a levonorgestrel - releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879–83.
  15. Tang G.W, Loa S.S. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception 1995; 51: 231–5.
  16. Kittelsen N, Istre О.A. A randomized study comparing levonorgestrel intrauterine system (LNG IUS) and transcervical resection of the endometrium (TRCE) in the treatment of menorrhagia: preliminary results. Gynaecol Endoscopy 1998; 7: 61–5.
  17. Hurskainen R, Teperi J, Rissanen P et al. Quality of life and cost - effectiveness of levonorgestrel - releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomized trial. Lancet 2001; 357: 273–7.
  18. Lahteenmaki P, Haukkamaa M, Puolakka J et al. Open randomized study of use of levonorgestrel intrauterine system as alternative to hysterectomy. BMJ 1998; 316: 112–6.
  19. Lethaby A.E, Cooke I, Rees M. Progesterone/progestogen-AQ2 releasing intrauterine systems versus either placebo or any AQ2 other medication for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 2: CD002126.
  20. Stewart A, Cummins C, Gold L et al. The effectiveness of the levonorgestrel - releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001; 108: 74–86.
  21. Hallberg L, Hogdahl A.M, Nilsson L, Rybo G. Menstrual blood loss: a population study. Acta Obstet Gynecol Scand 1966; 45: 320–51.
  22. Cohen B.J, Gibor Y Anemia and menstrual blood loss. Obstet Gynecol Surv 1980; 35: 597–618.
  23. Andersson K, Odlind V, Rybo G. Levonorgestrel - releasing and Ш copper - releasing (NovaT) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49: 56–72.
  24. Faundes A, Alvarez F, Brache V, Tejada A.S. The role of the levonorgestrel IUD in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gynecol Obstet 1988; 26: 429–33.
  25. Luukkainen T, Allonen H, Haukkamaa M et al. Effective contraception with the levonorgestrel - releasing intrauterine device: 12-month report of a European multicenter study. Contraception 1987; 36: 169–79.
  26. Barrington J.W, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997; 104: 614–6.
  27. Jones R.L, Critchley H.O. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 2000; 15 (suppl. 3): 162–72.
  28. Scholten P.C. The Levonorgestrel IUD: Clinical Performance and Impact on Menstruation [dissertation]. Utrecht, The Netherlands: 1989.
  29. Pike M.C, Ross R.K. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000; 65: 659–64.
  30. Schairer C, Lubin J, Troisi R et al. Menopausal estrogen and estrogen - progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485–91.
  31. Raudaskoski T.H, Lahti E.l, Kauppila A.J et al. Transdermal estrogen with a levonorgestrel - releasing intrauterine device for climacteric complaints: clinical and endometrial response. Am J Obstet Gynecol 1995; 172: 114–9.
  32. Vercellini P, Aimi G, Panazza S.J et al. A levonorgestrel - releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999; 72: 505–8.
  33. Fedele L, Bianchi S, Zanconato G et al. Use of a levonorgestrel - releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485–8.
  34. Fedele L, Bianchi S, Raffaelli R et al. Treatment of adenomyosis - associated menorrhagia with a levonorgestrel - releasing intrauterine device. Fertil Steril 1997; 68: 426–9.
  35. Fong Y.F, Singh K. Medical treatment of a grossly enlarged ade - rb nomyotic uterus with the levonorgestrel - releasing intrauterine system. Contraception 1999; 60: 173–5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).